{
    "code": "02023204",
    "url": "http:\/\/www.fda.gov.tw\/MLMS\/H0001D.aspx?Type=Lic&LicId=02023204",
    "time": "2016-11-18 20:19:26",
    "許可證字號": "衛署藥輸字第023204號",
    "註銷狀態": "已註銷",
    "註銷日期": "99\/05\/31",
    "註銷理由": "屆期未申請展延",
    "有效日期": "95\/06\/18",
    "發證日期": "90\/06\/18",
    "許可證種類": "製　劑",
    "舊證字號": "",
    "醫療器材級數": "",
    "通關簽審文件編號": "DHA00202320400",
    "中文品名": "利必妥合併療法（因治隆注射液六百萬單位﹨毫升合併瑞比達膠囊２",
    "英文品名": "REBETRON COMBINATION THERAPY PAK (INTRO A 6 MIU\/ML PLUS REBETOL 200MG\/CAP)",
    "適應症": "１．曾經使用ＡＬＰＨＡ－ＩＮＴＥＲＦＥＲＯＮ單一療法治療後又復發的慢性Ｃ型肝炎２．首次接受治療的慢性Ｃ型肝炎。",
    "劑型": "130膠囊劑",
    "包裝": "盒裝",
    "標籤、仿單及包裝加註": "",
    "藥品類別": "05限由醫師使用",
    "主成分略述": [
        "INTERFERONALPHA-2B,RIBAVIRIN"
    ],
    "限制項目": "02輸　入",
    "申請商名稱": "0617801100  先靈葆雅企業股份有限公司",
    "主製造廠": {
        "主製造廠": "",
        "製造廠名稱": "F230015000  SCHERING-PLOUGH (BRINNY) COMPANY",
        "製造廠廠址": "INNISHANNON, CO. CORK,",
        "製造廠公司地址": "",
        "": ""
    },
    "CCC號列": "30049071005 抗癌藥Anti-cancer preparations",
    "藥理治療分類": "",
    "ingredients": [
        {
            "成分類別": "主成分",
            "成分代碼": "0818000710",
            "成分名稱": "INTERFERON ALPHA- 2B",
            "含量描述": "6000000",
            "含量": "6000000.0000000000",
            "單位": "IU (I"
        },
        {
            "成分類別": "主成分",
            "成分代碼": "0818000800",
            "成分名稱": "RIBAVIRIN",
            "含量描述": "200",
            "含量": "200.0000000000",
            "單位": "MG"
        }
    ]
}